Transaction details
Avalo Therapeutics, Inc. (NASDAQ: AVTX) reported that its Chief Medical Officer, Doyle Mittie, sold 679 shares of common stock on April 1, 2026, at $16.00 per share, producing proceeds of $10,864. On the same date, Mittie exercised options to purchase 679 shares at an exercise price of $8.04, for a total exercise value of $5,459. The company’s share price has subsequently risen to $17.76, a gain that the filing describes as a 170% increase over the last 12 months.
Post-transaction holdings
Following the sale and option exercise, Mittie holds 3,622 shares of Avalo Therapeutics common stock. In addition, the filing indicates Mittie retains 148,329 stock options. The disclosed transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan that was adopted on November 13, 2025.
Analyst coverage and trial timelines
Separately, Avalo has garnered a series of analyst notes that underscore a favorable consensus view among several brokerages. Guggenheim reiterated a Buy rating and set a $50 price target following the company’s fiscal year 2025 earnings release. H.C. Wainwright raised its price target to $40, citing increased confidence in the company’s AVTX-009 candidate ahead of an expected Phase 2 data readout. BTIG maintained a Buy rating with a $40 price target, calling attention to anticipated trial outcomes for AVTX-009. TD Cowen also reiterated a Buy rating, pointing to the potential within Avalo’s ongoing Phase II programs.
Guggenheim analyst Yatin Suneja is noted as expressing optimism about Avalo’s IL-1β inhibitor, highlighting potential advantages versus competing approaches. The company confirmed that the Phase II LOTUS study in hidradenitis suppurativa is on a timeline with final patient enrollment expected by the end of March 2026.
Context and implications
The insider transaction reported here combined an option exercise with a contemporaneous sale of an identical number of shares executed under a pre-established trading plan. The market has moved higher since the sale price, with the stock trading at $17.76 at the time of the filing. Analyst commentary and target revisions cited in the filings emphasize confidence in AVTX-009 and Avalo’s broader Phase II efforts, with price targets and ratings from Guggenheim, H.C. Wainwright, BTIG, and TD Cowen noted in the disclosure.
Summary
- Doyle Mittie sold 679 shares at $16.00 and exercised 679 options at $8.04 on April 1, 2026.
- Transactions were carried out under a Rule 10b5-1 trading plan adopted November 13, 2025.
- Analysts from multiple firms reiterated Buy ratings or raised price targets ahead of Phase II readouts and enrollment milestones for AVTX-009 and the LOTUS study.